UB Paderborn / Katalog / Suche / in CDI

Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975

Journal of clinical oncology, 2003-11, Vol.21 (21), p.3909-3917

2003

Link zum Volltext

Verfügbarkeit prüfen

RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients

Diagnostics (Basel), 2020-12, Vol.11 (1), p.15

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 1999-01, Vol.17 (1), p.12-18

1999

Link zum Volltext

Verfügbarkeit prüfen

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

Clinical cancer research, 2003-01, Vol.9 (1), p.143-150

2003

Link zum Volltext

Verfügbarkeit prüfen

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-12, Vol.8 (12), p.1529-1537

2013

Link zum Volltext

Verfügbarkeit prüfen

Brain metastases from renal cell carcinoma. Should we change the current standard?

Cancer treatment reviews, 2012-06, Vol.38 (4), p.249-257

2012

Link zum Volltext

Verfügbarkeit prüfen

Malignant mesothelioma: New insights into a rare disease

Cancer treatment reviews, 2013-10, Vol.39 (6), p.584-591

2013

Link zum Volltext

Verfügbarkeit prüfen

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

Journal of thoracic oncology, 2020-07, Vol.15 (7), p.1232-1239

2020

Link zum Volltext

Verfügbarkeit prüfen

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

Lung cancer (Amsterdam, Netherlands), 2020-12, Vol.150, p.62-69

2020

Link zum Volltext

Verfügbarkeit prüfen

SEOM clinical guidelines for the management of adult soft tissue sarcomas

Clinical & translational oncology, 2012-07, Vol.14 (7), p.541-544

2012

Link zum Volltext

Verfügbarkeit prüfen

Lung cancer in Spanish women: The WORLD07 project

European journal of cancer care, 2019-01, Vol.28 (1), p.e12941-n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant treatment in resected non-small cell lung cancer: Current and future issues

Critical reviews in oncology/hematology, 2013-11, Vol.88 (2), p.375-386

2013

Link zum Volltext

Verfügbarkeit prüfen

Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07

Cancer investigation, 2017-05, Vol.35 (5), p.358-365

2017

Link zum Volltext

Verfügbarkeit prüfen

Cost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil)

European journal of hospital pharmacy. Science and practice, 2021-11, Vol.28 (e1), p.e13-e17

2021

Link zum Volltext

Verfügbarkeit prüfen

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9012-9012

2018

Link zum Volltext

Verfügbarkeit prüfen

First analysis of the National Lung Cancer Register in Spain (RTT)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13608-e13608

2018

Link zum Volltext

Verfügbarkeit prüfen

Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07

Anticancer research, 2016-12, Vol.36 (12), p.6647-6654

2016

Link zum Volltext

Verfügbarkeit prüfen

Complementary medicines in oncology

Atención primaria, 2007-01, Vol.39 (1), p.5-6

2007

Link zum Volltext

Verfügbarkeit prüfen

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

Clinical & translational oncology, 2017-03, Vol.19 (3), p.341-356

2017

Link zum Volltext

Verfügbarkeit prüfen

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2011-04, Vol.72 (1), p.84-91

2011

Link zum Volltext

Verfügbarkeit prüfen

Treatment strategies after failure to reversible tyrosine kinase inhibitors (rTKI) in EGFR mutant (mut) non-small cell lung cancer (NSCLC) patients (p): A retrospective analysis of 41 Spanish p

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e19089-e19089

2013

Link zum Volltext

Verfügbarkeit prüfen

SEOM guidelines for the treatment of malignant pleural mesothelioma

Clinical & translational oncology, 2011-08, Vol.13 (8), p.569-573

2011

Link zum Volltext

Verfügbarkeit prüfen

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer

Journal of clinical oncology, 1998-06, Vol.16 (6), p.2133-2141

1998

Link zum Volltext

Verfügbarkeit prüfen

Menstrual status and lung cancer in female patients from the Spanish WORLD07 database

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e12012-e12012

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975

RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients

Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

Brain metastases from renal cell carcinoma. Should we change the current standard?

Malignant mesothelioma: New insights into a rare disease

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

SEOM clinical guidelines for the management of adult soft tissue sarcomas

Lung cancer in Spanish women: The WORLD07 project

Adjuvant treatment in resected non-small cell lung cancer: Current and future issues

Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07

Cost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil)

Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group)

First analysis of the National Lung Cancer Register in Spain (RTT)

Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07

Complementary medicines in oncology

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

Treatment strategies after failure to reversible tyrosine kinase inhibitors (rTKI) in EGFR mutant (mut) non-small cell lung cancer (NSCLC) patients (p): A retrospective analysis of 41 Spanish p

SEOM guidelines for the treatment of malignant pleural mesothelioma

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer

Menstrual status and lung cancer in female patients from the Spanish WORLD07 database

Suchergebnisse filtern